We have leveraged our expertise in niche, difficult-to-develop and manufacture products to emerge as a preferred finished dosage player. The pharma business of Accord Pharma is led by IP-driven product licensing and marketing and distribution partnerships across the globe.

Accord Pharma is creating a strong pipeline of generics across varied formats and domains including Injectable sterile dosage forms and oral dosage forms and topicals.

Our domain strategy of developing a comprehensive product portfolio in oncology therapeutic segments has attracted partnerships in Regulated markets such as US, Europe, & Latin America.

Oncology Liquid & Lyophilized Injectable and OSD formulation products (ANDAs) under development, for regulated markets has more than 40 Oncology generic drugs, giving it one of the most comprehensive oncology portfolios in the world.

Our Oncology formulation products are intended for global filings across different geographies including US, EU markets.

Apart from oncology formulations, we are also backward integrating with manufacturing of Oncology APIs and other general APIs at our upcoming API facility for global supply, giving us control on quality and additional security of supply.

Our planned efforts on automation in the areas of manufacturing and laboratory shall create a conducive environment for Quality and Compliance.